DLX4

Across TCGA pan-cancer cohorts, DLX4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DLX4 data layer compared with 28 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher DLX4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DLX4 expression acts as an unfavorable survival marker.

KIRC, DLBC, and LGG are the cancer types where DLX4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.062	0.874	<.001	36	view →
DLBC	DFS	Median	III,IV	0.137	0.790	<.001	15	view →
LGG	OS	Median	All	0.034	0.909	<.001	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
PRAD	DFS	Median	All	0.118	0.886	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DLX4–KIRC (OS)

Open the KIRC breakdown →